Clinical Trials Logo

Waldenstrom Macroglobulinemia clinical trials

View clinical trials related to Waldenstrom Macroglobulinemia.

Filter by:

NCT ID: NCT03162536 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Start date: June 26, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.

NCT ID: NCT03147885 Recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Start date: June 20, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maximum tolerated dose of Selinexor in combination with RCHOP and also study the efficacy of this combination for therapy of B cell Non-Hodgkin's lymphoma. Giving Selinexor plus chemotherapy may work better in treating patients with B cell non-Hodgkin lymphoma.

NCT ID: NCT03133221 Active, not recruiting - Follicular Lymphoma Clinical Trials

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

Start date: October 23, 2017
Phase: Phase 2
Study type: Interventional

This is a pilot study to learn how safe and how effective the study drug Zydelig works, after autologous stem cell transplant as a maintenance therapy in patients with indolent or transformed indolent B-cell non-Hodgkins lymphoma (iNHL or tiNHL).

NCT ID: NCT03053440 Completed - Clinical trials for Waldenström's Macroglobulinemia

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

ASPEN
Start date: January 25, 2017
Phase: Phase 3
Study type: Interventional

This study evaluated the safety, efficacy and clinical benefit of BGB-3111 (zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.

NCT ID: NCT03037645 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Start date: April 28, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor where one is approved for the indication.

NCT ID: NCT03019666 Completed - Multiple Myeloma Clinical Trials

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

Start date: October 18, 2017
Phase: Phase 1
Study type: Interventional

This is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients with relapsed or refractory multiple myeloma (MM) or relapsed/refractory CD20-positive non-Hodgkin lymphoma (NHL). The primary endpoint of the study is to determine the maximum tolerated dose (MTD) of NAM-NK cells while maintaining safety.

NCT ID: NCT03015896 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Start date: February 14, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This I/II trial studies the side effects and best dose of lenalidomide when given together with nivolumab and to see how well they work in treating patients with non-Hodgkin or Hodgkin lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and lenalidomide may work better in treating patients with non-Hodgkin or Hodgkin lymphoma.

NCT ID: NCT03010358 Completed - Anemia Clinical Trials

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Start date: July 17, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effect and best dose of entospletinib when giving together with obinutuzumab and to see how well they work in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma that has come back. Entospletinib may stop the growth of cancer cells by blocking some of the enzymes need for cell growth. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Giving entospletinib and obinutuzumab together may work better in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma.

NCT ID: NCT02991898 Terminated - Multiple Myeloma Clinical Trials

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

Start date: February 16, 2017
Phase: Phase 2
Study type: Interventional

This is a single center pilot study of a non-myeloablative umbilical cord blood transplant for the treatment of a hematological malignancy with a single infusion of T regulatory (Treg) given shortly after UCB transplantation.

NCT ID: NCT02991638 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Start date: November 1, 2016
Phase: Phase 3
Study type: Interventional

Efficacy and Safety of ibrutinib in patients with chronic lymphocytic leukemia and other indolent B-cell lymphomas who are chronic hepatitis B virus carriers or occult hepatitis B virus carriers